- Company
- ‘Much work remains to be done for new drug access in Korea'
- by Eo, Yun-Ho May 20, 2024 05:42am
- Kyung-Eun Bae (Kay&160;Bae, 53) has risen to become the 'center' of the pharmaceutical industry. After being appointed as the general manager to lead subsidiaries including Korea, New Zealand, and Australia of the Sanofi Group, Bae was also appointed Chair of the Korean Research-based Pharmaceutical Industry Association (KRPIA) Being app
- Company
- Welireg can be prescribed in general hospitals in Korea
- by Eo, Yun-Ho May 20, 2024 05:41am
- Welireg, a rare anticancer drug for a small number of patients, can now be prescribed in general hospitals in Korea. According to industry sources on the 17th, MSD Korea’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, ‘Welireg (belzutifan) passed the drug committees (DCs) of various medical centers in Korea including the Na
- Company
- 'Imfinzi' shown to be effective for liver cancer
- by Son, Hyung-Min May 17, 2024 05:47am
- Imfinzi, an immunotherapy treatment for cancer, demonstrated effectiveness for liver cancer in addition to bile duct cancer. Consequently, it is expanding its uses in gastrointestinal cancer. AstraZeneca confirmed the effectiveness of Imfinzi in combination therapy with Imjudo, which targets CTL-A4, as a first-line treatment for liver canc
- Company
- Ferring Korea appoints Min-Jung Kim as new GM
- by Son, Hyung-Min May 17, 2024 05:47am
- On May 16, Ferring Pharmaceuticals Korea announced that the company appointed Min-Jung Kim as its new general manager, effective as of May 1. The new GM joined the company in 2021 as Chief Financial Officer (CFO). Kim has over 20 years of experience in finance, business development, SCM, IT, and human resources at global pharmaceutical an
- Company
- Repotrectinib receives orphan drug designation in Korea
- by Eo, Yun-Ho May 17, 2024 05:47am
- , The &160;ROS1-targeted lung cancer drug repotrectinib received an orphan drug designation in Korea. The Ministry of Food and Drug Safety (MFDS) announced the designation in a recent announcement. Specifically, the indications repotrectinib received orphan drug designation for are as follows: ▲ treatment for patients with ROS1-posit
- Company
- Chinese Pharmas show presence at BIO Korea 2024
- by Moon, sung-ho May 16, 2024 05:48am
- Chinese pharmaceutical companies are starting to enter the domestic pharmaceutical and biotechnology market in earnest. This was the main observation made by the Korean industry at ‘BIO Korea 2024,’ cohosted by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The activities of major Chinese phar
- Company
- Xcopri’s cumulative revenue surpasses KRW 1 trillion
- by Chon, Seung-Hyun May 16, 2024 05:48am
- Xcopri, SK Biopharmaceutical's new epilepsy drug, is continuing to show strong growth in the US market. Since its launch, sales have continued to rise every quarter, with cumulative sales exceeding KRW 600 billion. When including the revenue it had collected by licensing-out Xcopri’s technology, the company has secured more than KRW 1 trillion
- Company
- "Camzyos, reimbursement would benefit gov and patients"
- by Eo, Yun-Ho May 16, 2024 05:48am
- The reason for delayed drug development in a particular disease typically falls into one of two. It’s either low awareness of the disease or challenges to drug development. Despite falling into these two categories, 'Camzyos (mavacamten)' was developed. It is a first-in-class targeted treatment option for obstructive hypertrophic cardi
- Company
- New oral psoriasis drug 'Sotyktu' available in hospitals
- by Eo, Yun-Ho May 14, 2024 05:48am
- An oral psoriasis drug 'Sotyktu' is becoming available for prescription at general hospitals. According to industry sources, BMS Korea’s Sotyktu (deucravacitinib) has passed the drug committee (DC) of hospitals, including Seoul Asan Hospital, Severance Hospital, Konyang University Hospital, Soonchunghyang University Bucheon Hospital, Se
- Company
- Ryvrevant to lead market with Exkivity’s market withdrawal
- by Son, Hyung-Min May 14, 2024 05:48am
- Exkivity, a treatment for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation, is being withdrawn from the market. The highly anticipated oral treatment failed to demonstrate efficacy in a confirmatory clinical trial, leading to its market withdrawal. With no competition, Rybrevant is expected to remain the market leader
